Beam Therapeutics (BEAM) Stock Forecast & Price Target

Beam Therapeutics is viewed favorably because its lead asset BEAM-302 is showing durable, mutation-correcting efficacy in AATD, with follow-up now extending to 18 months, 29 efficacy-evaluable patients, and mean steady-state total AAT above the 11 µM protective threshold at the 60 mg dose. The company’s pipeline also has multiple near-term catalysts, including a global pivotal BEAM-302 cohort already dosing, risto-cel on track for a BLA filing as early as year-end 2026, and the FDA-cleared BEAM-304 umbrella IND that can efficiently expand into multiple PKU mutations. Financially, Beam’s roughly $1.15 billion to $1.2 billion cash position and runway into mid-2029 reduce funding risk while it advances these programs.

Beam Therapeutics is viewed negatively because its pipeline remains highly exposed to clinical and safety execution risk, with poorer-than-expected data, off-target activity, or other unanticipated safety signals potentially undermining every product candidate. Its lead programs still carry only modest stated probabilities of success—45% for BEAM-101 and BEAM-103/104 in SCD, 30% for BEAM-302 in AATD, and 30% for BEAM-301 in GSDIa—while competition, reimbursement, pricing, and commercialization risks could materially limit adoption and market potential. The valuation framework also assumes $200M of annual gross capital raises from 2027E to 2030E, creating meaningful dilution risk, even before considering the uncertainty around collaboration revenue and the broader novel-modality risk of base editing therapies.